BioRestorative Therapies, Inc.(BRTX)Earnings, Financials & Key Ratios

MELVILLE, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX ), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced the successful completion of manufacturing for its BRTX-100 Phase 2 clinical trial, marking a key milestone in the development of its lead cell therapy candidate and underscoring the strength of the Company's vertically integrated regenerative medicine platform.

Accomplished commercial aesthetics veteran to drive sales channel expansion and pipeline development MELVILLE, N.Y., June 18, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX ), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced the appointment of Zachary Smith as Vice President of its Biocosmeceuticals Division, further strengthening the Company's commercial leadership team as it expands its presence within the regenerative aesthetics and advanced skincare market.